Cota Announces Data and Technology Collaboration with Memorial Sloan Kettering Cancer Center to Advance Personalized Cancer Treatment and Research

NEW YORK, Nov. 9, 2017 /PRNewswire/ -- Cota Inc., a healthcare data and analytics company bridging precision medicine to population health, today announced a multi-year partnership with Memorial Sloan Kettering Cancer Center (MSK), one of the world's most renowned cancer centers.

As part of the collaboration, MSK will provide Cota with anonymized clinical data. Through its unique classification system, the Cota Nodal Address™ (CNA), Cota will construct optimized clinical and genomic datasets from the MSK records, and the resulting datasets will help MSK improve patient care and advance its world-leading research efforts. These datasets will also further enable Cota to expand its real-world evidence database with the intention of improving clinical outcomes, reducing total cost of care in the field of oncology and gleaning actionable insights to advance cancer treatment discoveries and health outcomes.

MSK and Cota will also form a technology collaboration focused on advanced analytics to enable more consistent disease classification within oncology, which could help drive further insights for both researchers and physicians.

"We are very excited to partner with Memorial Sloan Kettering, one of the world's leading cancer centers, and merge their unmatched experience in cancer research and patient care with our innovative approach to data analytics," said John Hervey, chief executive officer of Cota. "By combining the precision of our Cota Nodal Address system with Memorial Sloan Kettering's robust datasets, clinical expertise and outstanding record of success, together we will advance how the industry leverages data analytics to improve cancer patient care."

The CNA is a new digital classification system designed to precisely categorize patient factors, their diseases and intended therapies by creating cohorts of similar patients. The CNA represents a digital compression of the biologic narrative, similar to the bar-code systems used in retail industries, that ultimately makes electronic medical record information useful for patients and healthcare professionals. With diseases precisely defined and characterized by the CNA structure, big data analytic techniques become possible, precision medicine is enabled and value-based medicine can be optimized. 

"Memorial Sloan Kettering doctors and researchers are constantly innovating in an effort to provide the best care to our patients, but some of that rich experience and knowledge is obscured in individual patients' clinical records," said Paul Sabbatini, M.D., deputy physician-in-chief for clinical research at Memorial Sloan Kettering. "Working with Cota, which has a unique approach to transforming clinical data such as ours, will help us have a more robust understanding of the components that make up a patient's diagnosis and care pathway. This organized and analyzed data will help our physicians practice more efficiently, optimizing the care a patient receives based on a variety of characteristics and ultimately can improve outcomes for all cancer patients as this knowledge is shared."  

"Collaborations like this not only democratize the expertise of MSK, but also enable the delivery of precision medicine at scale by building real-world evidence that is digitally organized in a manner that is relevant to various stakeholders through the Cota CNA," said Scott Paddock, president & chief operating officer, Cota. "Furthermore, the CNA system offers the tools for providers and payers to deliver value-based care, providing the data to avoid adverse variance (too much or too little care), thus optimizing clinical outcomes for each patient and reducing the total cost of care for the population served. Researchers can also leverage a deeper and richer set of real-world evidence to fuel more efficient and effective development of new cancer treatments."

"Cota's powerful technology platform can thread disparate data into a rich longitudinal record to support hypothesis testing, actionable insights and evidence based decision-making," said Janhvi Patel, vice president of strategic partnerships at Cota. "This collaboration puts Cota at the forefront of precision medicine, creating one of the richest clinical and genomic databases in cancer to fuel innovation in research and development of new therapies and payer-provider value-based programs."

To join us in our mission to enable optimal clinical outcomes for every individual and reduce the total cost of care for the population served, contact Eva Werk, vice president of marketing at Cota [email protected].

About Cota
Cota is a healthcare data and analytics company that enables providers, payers and life science companies involved in diagnosing and treating complex diseases to optimize the outcomes of individual patients and lower the overall cost of the patient population served. It is powered by the patented Cota Nodal Address™ (CNA) system, a unique digital classification methodology built by leading physicians and data scientists. The CNA is the first and only system that precisely categorizes patient factors, their diseases and intended therapies, enabling precision medicine at scale.

Cota's technology enriches medical records to create research-grade data and joins it with a suite of analysis, visualization and management tools. This enables providers, payers and life science companies to analyze, report on and research outcomes, costs, treatments and quality at any granularity and stage of the patient journey. The result is a constantly improving system that merges technology and medicine to improve the lives of patients everywhere. For more information, go to www.cotahealthcare.com

Media Contact:

Alessandra Nix
SHIFT Communications
[email protected]
617.779.1860

SOURCE Cota

Related Links

https://www.cotahealthcare.com